Is Alchemix a Good Investment?

C-Value
C+Risk
|Lending
Loading price data...
TVL$30M
FDV$16M
TVL/FDV1.92x
Risk GradeC+
Value GradeC-

Value Accrual: Does the Alchemix Token Capture Value?

Alchemix scores C- on Hindenrank's value accrual framework (42/100), indicating average value capture — some strengths offset by weaknesses in fee distribution or sustainability. Fee capture scores 9/25 — limited, with most protocol revenue not yet accruing to the token. Token distribution is rated 6/25 (significantly concentrated among insiders or early investors), and emission sustainability sits at 16/25. The competitive moat dimension scores 11/25.

Scored as: Business
Fee Capture
9/25
Token Distribution
6/25
Emission Sustainability
16/25
Competitive Moat
11/25

Protocol Health: Is Alchemix Still Growing?

Alchemix's vitality risk score is 7/10 on Hindenrank's rubric (lower is healthier). This raises concerns about protocol vitality — Alchemix shows signs of declining activity, stagnant or falling TVL, or reduced developer engagement. Investors should monitor whether this trend reverses before increasing exposure.

Risk-Adjusted View: Is the Upside Worth the Risk?

Risk-Adjusted Position

Neutral
High Value
Medium Value
Low Value
High Risk
High Risk Play
Risky
Avoid
Medium Risk
Promising
Alchemix
Weak
Low Risk
Blue Chip
Safe but Stale
Dead Money
See all Neutral protocols →

Alchemix sits in the Neutral zone — average on both risk (C+) and value (C-). There is no strong reason to overweight or avoid the token at current levels. Monitor for catalysts that could shift the balance in either direction.

Risk Context

Alchemix carries a risk grade of C+ (36/100), classified as elevated risk — multiple novel mechanisms and notable interaction risks. While no critical-severity interactions were identified, 2 high-severity interactions warrant attention. The primary risk factor is: Self-repaying loan model depends entirely on sustained yield generation from underlying strategies. If yields go to zero, loans never repay and collateral is locked indefinitely.

Read our full safety analysis →

Should you buy Alchemix?

Alchemix scores C- on Hindenrank's value accrual framework, placing it among the average Lending protocols. Fee capture scores 9/25 — limited, with most protocol revenue not yet accruing to the token. Token distribution is significantly concentrated among insiders or early investors, and emission sustainability sits at 16/25. On the risk side, Alchemix carries a C+ grade (36/100), which is elevated risk — multiple novel mechanisms and notable interaction risks. The combined risk-value position places Alchemix in the Neutral quadrant.

Alchemix investment outlook for 2026

With $30M in total value locked and FDV of $16M, giving a TVL/FDV ratio of 1.92, Alchemix's fundamentals do not strongly support the current valuation from a usage perspective. The competitive moat dimension scores 11/25, suggesting limited moat, leaving the protocol vulnerable to competitive pressure.Investors should weigh these fundamentals alongside market conditions and their own risk tolerance.

This analysis is based on cryptoeconomic fundamentals, not price prediction. It is not financial advice. Full methodology

Weekly Commentary

Pro

Week of March 3, 2026

Alchemix's self-repaying loan model is genuinely novel but the C+ risk grade reflects real mechanism complexity — synthetic debt backed by yield-bearing collateral creates layered dependency risk that compounds during market stress. At $30M TVL the protocol has shed significant scale from its peak, and the C- value grade signals weak fee capture relative to token dilution. A neutral quadrant read is fair: interesting technology, but neither the risk profile nor the value accrual makes a compelling case to size up.

Related Lending Investment Analyses

Related Lending Safety Analyses

Investment analysis uses Hindenrank's value accrual framework across four dimensions: fee capture, token distribution, emission sustainability, and competitive moat. Higher score = better value accrual. Combined with our eight-dimension risk rubric for risk-adjusted positioning. This is not financial advice.